There are many reports on grapefruit juice (GFJ) increasing the apparent oral bioavailability of several clinically important drugs metabolized by the most abundant isoform of cytochrome P450, i. e. CYP 3A4. Azelnidipine (Calblock (R)) is a long-lasting 1, 4-dihydropyridine calcium antagonist currently used in the treatment of hypertension in Japan. In a drug interaction study using human liver microsomes, several CYP3A4 inhibitors and substrates inhibited the oxidative metabolism of azelnidipine to the same extent as nifedipine and felodipine. In order to evaluate the possible interaction of azelnidipine with GFJ in humans , a randomized, two-way crossover study was conducted in eight Japanese healthy volunteers.
Introduction
It is well known that more than half of the cur rently available drugs are metabolized by cyto chrome P450 3A4 (CYP3A4), a major isoform in human 1). Recently it has been reported that CYP3A 4 expressed in the apical lumen of the small intes tine participates in presystemic clearance of exogenous substances including drugs as well as that expressed in the hepatocytes. Thereby, when a drug mainly metabolized by CYP3A4 in the small intestine is administered orally, the enzyme plays a significant role in regulating the extent and rate of bioavailability of the drug.
Azelnidipine (Calblock (R)) is a L-type calcium channel selective antagonist, which is categorized as third generation type-B2). The remarkable char acteristics of azelnidipine that differentiate it from other analogues are 1) the lower possibility to cause sinus bradycardia in patients and, 2) longer lasting pharmacological effects even with a once daily dose of 8-16 mg 3).
Metabolism of azelnidipine was inhibited by sev eral CYP3A4 inhibitors and substrates to the same extent as nifedipine and felodipine in a previous in vitro drug interaction study using human liver microsomes 4). Numerous reports have shown that concomitant ingestion of grapefruit juice (GFJ) results in an increase in the plasma concentrations of several drugs in clinical use5-13). In our previous study, we clarified that prior GFJ ingestion signifi cantly alters the pharmacokinetic behavior of ator vastatin, namely an increase of systemic exposure of both parent acid and lactone forms accompanied with a decrease of 2-hydroxyl metabolites.
In con trast, no significant changes were detected in any pharmacokinetic parameters of pravastatin examined when taken with GFJ 13). This increase of systemic exposure is considered to be due to the mechanism-based inhibition of CYP 3A4 activities in the small intestine by subsequent reduction in presystemic metabolic clearance 14).
Indeed after intravenous administration, the plasma levels of these drugs were not altered by GFJ ingestion 15).
Concomitant ingestion of GFJ with dihydropyr idine calcium antagonists was reported to induce several overdose-like vascular-related adverse events, such as headache, flushing and accelerating heart rate, even though the studies were performed with healthy adults 15,16).
There are also some reports of an increase in the risk of side effects of anxiolytic agents administer ed with GFJ 17, 18) . In the most recently reported cases, however, the effects were mild and not con sidered clinically significant. Caution should be paid especially for drugs with a small therapeutic range and/or more likely to induce a pharmaco logical over-response when taking GFJ.
In the present study, we investigated the extent of drug interaction between azelnidipine and GFJ in Japanese healthy male volunteers.
Methods

Subjects
Eight healthy male volunteers (age range; [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] years; weight range; 53.0-73.0kg) participated in the study as shown in Table 1 . Each subject was ascertained to be in good health by a medical history, a clinical examination and routine labora tory tests. The subjects were not taking any other continuous medication, and all of them were non smokers. They were not allowed to consume any grapefruit products during the study period from 1 week before the day of first dosing to the day after discharge from the hospital. This study was con ducted between September 11, 1998 and October 13, 1998 at the Medical Corporation Keiyu-Kai, Obara Hospital, Tokyo, Japan, in compliance with good 
Study design
The study was performed with a randomized, open-labeled two-way crossover design with an interval of 1 week. The volunteers ingested 250mL of 100% grapefruit juice (Tropicana TM Homemade Style, Kirin Beverage Corp., Tokyo, Japan:Lot No. # 0293) or water (250mL) on the day of each treatment at 9:00 a.m. with one 8 mg tablet of azelnidipine (Sankyo Co., Ltd., Tokyo, Japan). The subjects fasted for 14 hours before administra tion of azelnidipine, and a standardized meal and light snack were served at 4 hours and 7 hours after taking the test substance, respectively. The subjects were not allowed to smoke cigarettes, to drink alcohol, coffee or tea, or to take St. John's Wart during the study from 1 week before admission to the hospital to the day after discharge from the hospital.
Safety evaluation
Safety assessment was performed throughout the study including vital signs (body temperature, systolic and diastolic blood pressure, and pulse rate), electrocardiography, hematology, clinical chemistry and urinalysis as well as clinical obser vations (subjective and/or objective symptoms). Adverse events were monitored and recorded appropriately.
Blood sampling
Venous blood (10mL) was collected from the brachial vein of each subject just before administra tion of azelnidipine and 1/2, 1, 2, 3, 4, 6, 8, 12 and 24 hrs after administration. Blood was sampled into a siliconized Venoject tube and the plasma portion was separated within 30 minutes and stored at until analysis.
Determination of azelnidipine in plasma
Plasma concentrations of azelnidipine were determined by a prevalidated liquid chroma tography-tandem mass spectrometry (LC/APCI MS/MS TSQ7000, Finnigan MAT Instruments, Inc.) at BML Inc. (Tokyo, Japan) in compliance with good laboratory practice. The lower limit of quantification was 0.6ng/mL. The intra-and inter assay accuracy (RE) ranged from-8.6% to +6.1% for three different QC samples and met the predefined analytical criteria throughout the analy sis.
Pharmacokinetic analysis
The pharmacokinetics of azelnidipine was char acterized by a series of non-compartmental param eters, i. e. peak plasma concentration (Cmax), time to reach Cmax (tmax) mean residence time (MRT), elimination half-life (t1/2), area under the plasma. concentration-time curve (AUC0-24h) and appar ent oral clearance (CL/F). These parameters were calculated based on the individual plasma concen trations using commercially available software, WinNonlinTM (ver. 1.5, Pharsight). Figure  1 , and the details of the non-compartmental pharmacokinetic parameters are summarized in Table  2 .
Concomitant ingestion with GFJ increased the systemic exposure of azelnidipine as follows. The geometric means of the C. of azelnidipine in the GFJ treatment and water treatment were 15.7ng/ mL (95% CI:12.8-19.2) and 6.3ng/mL (95% CI:5.6-7.0), respectively. The Cmax showed a 2.5-fold increase (95% CI:2.12-2.95; p<0.01) by GFJ.
The geometric means of the AUC0-24h in the GFJ treatment and water treatment were 147.9ng-hr/ mL (95% CI:120.6-181. 4) and 45.1ng-hr/mL (95% CI:39.0-52.0), respectively. The AUC0-24h showed a 3.3-fold increase (95% CI:2.89-3.73; p<0.01) by GFJ.
The arithmetic means of the tmax in the GFJ treatment and water treatment were 2.1hr (95% CI:1.8-2.4) and 3.9hr (95% CI:3.0-4.7), respectively and the difference was statistically significant (p<0.01).
The arithmetic means of CL/F in the GFJ treat ment and water treatment were 926mL/min (95% CI:723-1,129) and 2, 998mL/min (95% CI: 2, 585-3, 412), respectively and the difference was statistically significant (p<0.01). However, there was no statistically significant difference in the t1/2 between the GFJ group and water group.
No serious drug-related adverse events were observed throughout the study. One subject (No. 1) described mild and possibly drug-related symptoms such as headache and facial flushing at 4hrs after azelnidipine administration with GFJ. This subject also showed a temporal orthostatic hypotension (Fig. 2) , which disappeared soon without any medi cal treatment and was not reproducible. are not absorbed from the gastrointestinal tract and are localized there at a substantially high level, the action is just limited to CYP3A4 expressed in the gut to eventually increase the intestinal first pass bioavailability (fg). The irreversible nature of inhibition prolongs the effect beyond a few days, which is governed by the enzyme turnover rate corresponding to a half-life of 8.16hrs 22). In particu lar, calcium antagonists are the most frequently reported for food-drug interactions with GFJ. Like wise, an increase in systemic exposure of azel nidipine, a dihydropyridine calcium antagonist, was observed with ingestion of GFJ in the present study.
In this study, a remarkable increase of 2.5 fold for Cmax and 3.3 fold for AUC0-24h was found after concomitant ingestion of GFJ and azelnidipine. In previously reported GJF interaction studies with calcium antagonists such as felodipine, nisoldipine, nifedipine and amlodipine under similar study designs, the magnitude of systemic exposure (AUC) increase by GFJ were quite different among the drugs:2.84 fold for felodipine6), 4.06 The mean t1/2 of azelnidipine seemed to be slight ly prolonged from 6.5hr in the control group to 7.7 hr in the GFJ group. However, there was no statisti cally significance. In contrast, the apparent oral clearance (CL/F) was significantly decreased by GFJ ingestion. Similar findings have been reported for other dihydropyridine calcium antagonists, such as in the felodipine-GFJ interaction study 14) . These results suggested that the concomitant effect of GFJ might be limited to the intestine and GFJ did not affect the liver. The inter-individual variability of Cmax and AUC0-24h in this study (corrected for body weight) was comparable between two treat ment phases and was somewhat smaller than those of three calcium antagonists under extensive CYP3 A4 metabolism 24).
Following concomitant administration with GFJ, different magnitudes of change in the AUC and Cmax were observed among various drugs 6), and in particular there was a clear relationship with the first pass bioavailability of several dihydropyridine calcium antagonists 7). The absolute bioavail abilities in healthy subjects were as follows:less than 10% for nisoldipine 16), 13-21% for felodipine 25), 50-60% for nifedipine 26) and 81% for amlodipine 27).
It is noteworthy that a drug with a lower absolute bioavailability tends to show a greater increase in the exposure after concomitant ingestion of GFJ. However, it is also known that the content of CYP 3A4 and its distribution in the intestine are variable among subjects6). Considering 30-fold difference in activity and content of CYP3A4 among individuals28), we should select the appropriate drug for each patient based on the balance of efficacy and any adverse symptoms during therapy.
The first pass metabolism of azelnidipine via CYP3A4 expressed at the intestine might be sub stantially inhibited by GFJ ingestion. No serious drug-related adverse effects were observed in this study even though the magnitude of systemic expo sure increase by GFJ ingestion was rather high compared with other dihydropyridine calcium antagonists. One subject (No. 1) described headache and facial flushing at 4 hrs after drug adminis tration with GFJ. A temporal and not reproducible orthostatic hypotension was also observed ac companied with these possibly drug-related symp toms. Interestingly, the systemic exposure of this subject at the GFJ phase was not as high compared with the other seven subjects (Fig. 3) . Considering the hypotensive background of this subject (Table  1) , the latter symptom might be caused by baro receptor reflex impairment commonly occurring in such a population. In a previous felodipine and GFJ interaction study, both flushing and headache were observed in or reported by all subjects due to vasodilatation, although these symptoms were mild and did not lead to the withdrawal of any subjects from the study29).
An in vitro study showed that azelnidipine rever sibly blocks voltage-dependent Ca2+influx through L-type calcium channels in the cell membrane30). Azelnidipine exerts a long duration of phar macological action due to its high lipophilicity31), which the first or second generation of calcium channel antagonists do not exhibit. The elimination half-life of azelnidipine in healthy subjects mar ginally deviates among the reported studies19,32,33); the summarized average ranges from 7 to 21 hrs, which is nevertheless longer than those of common ly used calcium antagonists except for amlodipine2). The temporal orthostatic hypotension observed in subject No. 1 did not accompany high systemic exposure of drug, however, there is a concern that the concomitant intake of azelnidpine with GFJ chronically may cause significant elevation of the plasma level and a drug-related adverse reaction in patients.
Consequently, an appropriate warning should be given for patients not taking GFJ during azelnidipine therapy. In this study, we investigated the effect of a single glass of GFJ on the oral bioavailability of azelnidipine.
Considering the pharmacokinetic and pharmacodynamic characteristics of azelnidipine, the possibility of any drug-drug interaction with concomitantly prescribed CYP3A4 related drugs should also be investigated.
Note:A part of this study was previously described in the package insert of Calblock(R) (Sankyo).
